David S. Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David S. Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Gloria L. Hwang
Division of Interventional Radiology, Stanford Health Care, Stanford, CA, United States
27 shared publications - Ajay Subramanian
Department of Radiation Oncology, Stanford University, Stanford, CA, USA
26 shared publications - Everett J. Moding
Department of Radiation Oncology, Stanford University, Stanford, CA
26 shared publications - Gregory W. Charville
Stanford University School of Medicine
26 shared publications - Hans-Christoph Becker
Department of Radiology, Stanford University, Stanford, California
26 shared publications - Ileana A. Torres
Division of Oncology, Department of Medicine, Stanford University, Stanford, California
26 shared publications
Latest Publications
- 5 August 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Trajectory-Based Trauma Index and Pleural Infiltration Predict Pneumothorax After CT-Guided Lung Cryoablation
- 5 August 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Trajectory-Based Trauma Index and Pleural Infiltration Predict Pneumothorax After CT-Guided Lung Cryoablation
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Purpose:Immune checkpoint inhibition has led to promising responses in soft tissue sarcomas (STS), but the majority of patients do not respond and biomarkers of response will be crucial. Local ablative therapies may augment systemic responses to immunotherapy. We evaluated circulating tumor DNA (ctDNA) as a biomarker of response in patients treated on a trial combining immunotherapy with local cryotherapy for advanced STS.Patients and Methods:We enrolled 30 patients with unresectable or metastatic STS to a phase II clinical trial. Patients received ipilimumab and nivolumab for four doses followed by nivolumab alone with cryoablation performed between cycles 1 and 2. The primary endpoint was objective response rate (ORR) by 14 weeks. Personalized ctDNA analysis using bespoke panels was performed on blood samples collected prior to each immunotherapy cycle.Results:ctDNA was detected in at least one sample for 96% of patients. Pretreatment ctDNA allele fraction was negatively associated with treatment response, progression-free survival (PFS), and overall survival (OS). ctDNA increased in 90% of patients from pretreatment to postcryotherapy, and patients with a subsequent decrease in ctDNA or undetectable ctDNA after cryotherapy had significantly better PFS. Of the 27 evaluable patients, the ORR was 4% by RECIST and 11% by irRECIST. Median PFS and OS were 2.7 and 12.0 months, respectively. No new safety signals were observed.Conclusions:ctDNA represents a promising biomarker for monitoring response to treatment in patients with advanced STS, warranting future prospective studies. Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STS to immunotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
Purpose:Immune checkpoint inhibition has led to promising responses in soft tissue sarcomas (STS), but the majority of patients do not respond and biomarkers of response will be crucial. Local ablative therapies may augment systemic responses to immunotherapy. We evaluated circulating tumor DNA (ctDNA) as a biomarker of response in patients treated on a trial combining immunotherapy with local cryotherapy for advanced STS.Patients and Methods:We enrolled 30 patients with unresectable or metastatic STS to a phase II clinical trial. Patients received ipilimumab and nivolumab for four doses followed by nivolumab alone with cryoablation performed between cycles 1 and 2. The primary endpoint was objective response rate (ORR) by 14 weeks. Personalized ctDNA analysis using bespoke panels was performed on blood samples collected prior to each immunotherapy cycle.Results:ctDNA was detected in at least one sample for 96% of patients. Pretreatment ctDNA allele fraction was negatively associated with treatment response, progression-free survival (PFS), and overall survival (OS). ctDNA increased in 90% of patients from pretreatment to postcryotherapy, and patients with a subsequent decrease in ctDNA or undetectable ctDNA after cryotherapy had significantly better PFS. Of the 27 evaluable patients, the ORR was 4% by RECIST and 11% by irRECIST. Median PFS and OS were 2.7 and 12.0 months, respectively. No new safety signals were observed.Conclusions:ctDNA represents a promising biomarker for monitoring response to treatment in patients with advanced STS, warranting future prospective studies. Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STS to immunotherapy.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Supplementary Data 1 from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Purpose: Immune checkpoint inhibition has led to promising responses in soft tissue sarcomas (STSs), but the majority of patients do not respond and biomarkers of response will be crucial. Local ablative therapies may augment systemic responses to immunotherapy. We evaluated circulating tumor DNA (ctDNA) as a biomarker of response in patients treated on a trial combining immunotherapy with local cryotherapy for advanced STSs. Experimental Design: We enrolled 30 patients with unresectable or metastatic STS to a phase 2 clinical trial. Patients received ipilimumab and nivolumab for 4 doses followed by nivolumab alone with cryoablation performed between cycles 1 and 2. The primary endpoint was objective response rate (ORR) by 14 weeks. Personalized ctDNA analysis using bespoke panels was performed on blood samples collected prior to each immunotherapy cycle. Results: ctDNA was detected in at least one sample for 96% of patients. Pre-treatment ctDNA allele fraction was negatively associated with treatment response, progression-free survival (PFS), and overall survival (OS). ctDNA increased in 90% of patients from pre-treatment to post-cryotherapy, and patients with a subsequent decrease in ctDNA or undetectable ctDNA after cryotherapy had significantly better PFS. Of the 27 evaluable patients, the ORR was 4% by RECIST and 11% by irRECIST. Median PFS and OS were 2.7 and 12.0 months, respectively. No new safety signals were observed. Conclusions: ctDNA represents a promising biomarker for monitoring response to treatment in advanced STS, warranting future prospective studies. Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STSs to immunotherapy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis
Purpose: Immune checkpoint inhibition has led to promising responses in soft tissue sarcomas (STSs), but the majority of patients do not respond and biomarkers of response will be crucial. Local ablative therapies may augment systemic responses to immunotherapy. We evaluated circulating tumor DNA (ctDNA) as a biomarker of response in patients treated on a trial combining immunotherapy with local cryotherapy for advanced STSs. Experimental Design: We enrolled 30 patients with unresectable or metastatic STS to a phase 2 clinical trial. Patients received ipilimumab and nivolumab for 4 doses followed by nivolumab alone with cryoablation performed between cycles 1 and 2. The primary endpoint was objective response rate (ORR) by 14 weeks. Personalized ctDNA analysis using bespoke panels was performed on blood samples collected prior to each immunotherapy cycle. Results: ctDNA was detected in at least one sample for 96% of patients. Pre-treatment ctDNA allele fraction was negatively associated with treatment response, progression-free survival (PFS), and overall survival (OS). ctDNA increased in 90% of patients from pre-treatment to post-cryotherapy, and patients with a subsequent decrease in ctDNA or undetectable ctDNA after cryotherapy had significantly better PFS. Of the 27 evaluable patients, the ORR was 4% by RECIST and 11% by irRECIST. Median PFS and OS were 2.7 and 12.0 months, respectively. No new safety signals were observed. Conclusions: ctDNA represents a promising biomarker for monitoring response to treatment in advanced STS, warranting future prospective studies. Combining cryotherapy and immune checkpoint inhibitors did not increase the response rate of STSs to immunotherapy.